Novo Nordisk AS (HAM:NOV) Short Interest


HAM:NOV Novo Nordisk AS HAM:NOV
83 GF Score
Price €41.97
GF Value €120.51
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

HAM:NOV vs LLY, JNJ, ABBV: Short Interest Comparison

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk AS Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Short Interest distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Short Interest falls into.


HAM:NOV
83GF Score
Novo Nordisk AS HAM:NOV
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novo Nordisk AS (HAM:NOV) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €41.97 is trading 65.2% below its estimated GF Value™ of €120.51. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for HAM:NOV:

  • Short Interest:
  • GF Value™: €120.51 vs. price of €41.97 (65.2% below fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the HAM:NOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
83GF Score

Get the complete analysis for HAM:NOV

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€41.97
Price
€120.51
GF Value